aod9604 igf-1 effects Aod 9604 Peptide 2 5mg Peptide Therapy Weight Loss in

Reconstitution math for the 50 mg 5-Amino-1MQ vial BAC water added 1.0 mL Concentration 50.0 mg/mL 1 unit (U-100) equals 0.50 mg (500 mcg) BAC water added 2.0 mL Concentration 25.0 mg/mL 1 unit (U-100) equals 0.25 mg (250 mcg) BAC water added 3.0 mL Concentration 16.7 mg/mL 1 unit (U-100) equals 0.167 mg (167 mcg) Use 3.0 mL as the maximum BAC-water volume for this 50 mg vial format

Real Results

Studies in mice confirmed that animals lacking beta-3 receptors showed no response to AOD-9604, proving this pathway is essential to the mechanism

A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007